This free script provided by
JavaScript Kit


Catalog #:


Shipping advice:

Suitable for Express Delivery only (1-day). International shipping rate please contact us for details

IN0099-5mg USD79.0

References for TRAM 34:

1. Chen, Y. J., Raman, G., Bodendiek, S., O'Donnell, M. E., and Wulff, H. The KCa3.1 blocker TRAM-34 reduces infarction and neurological deficit in a rat model of ischemia/reperfusion stroke. J Cereb Blood Flow Metab.

2. Roy, J. W., Cowley, E. A., Blay, J., and Linsdell, P. The intermediate conductance Ca2+-activated K+ channel inhibitor TRAM-34 stimulates proliferation of breast cancer cells via activation of oestrogen receptors. Br J Pharmacol, 159: 650-658.

3. Al-Ghananeem, A. M., Abbassi, M., Shrestha, S., Raman, G., Wulff, H., Pereira, L., and Ansari, A. Formulation-based approach to support early drug discovery and development efforts: a case study with enteric microencapsulation dosage form development for a triarylmethane derivative TRAM-34; a novel potential immunosuppressant. Drug Dev Ind Pharm, 36: 563-569.

4. Tharp, D. L., Wamhoff, B. R., Wulff, H., Raman, G., Cheong, A., and Bowles, D. K. Local delivery of the KCa3.1 blocker, TRAM-34, prevents acute angioplasty-induced coronary smooth muscle phenotypic modulation and limits stenosis. Arterioscler Thromb Vasc Biol, 28: 1084-1089, 2008.

5. Schilling, T. and Eder, C. TRAM-34 inhibits nonselective cation channels. Pflugers Arch, 454: 559-563, 2007.

6. Wulff, H., Gutman, G. A., Cahalan, M. D., and Chandy, K. G. Delineation of the clotrimazole/TRAM-34 binding site on the intermediate conductance calcium-activated potassium channel, IKCa1. J Biol Chem, 276: 32040-32045, 2001.

Certificate of Analysis/MSDS is available upon request with lot number

Home | Contact | Support | Privacy Policy, Terms Warranty | Apycom jQuery Menus